Home LiteratureArticle Details
PMID: 17306896 Published · ppublish English Journal Article Review

The c-jun kinase/stress-activated pathway: regulation, function and role in human disease.

Biochimica et biophysica acta ·Vol. 1773 ·No. 8 ·2007-08-00 ·Pages 1341-8

Johnson GL, Nakamura K

Abstract

c-Jun N-terminal kinases (JNKs), also referred to as stress-activated kinases (SAPKs), were initially characterized by their activation in response to cell stress such as UV irradiation. JNK/SAPKs have since been characterized to be involved in proliferation, apoptosis, motility, metabolism and DNA repair. Dysregulated JNK signaling is now believed to contribute to many diseases involving neurodegeneration, chronic inflammation, birth defects, cancer and ischemia/reperfusion injury. In this review, we present our current understanding of JNK regulation and their involvement in homeostasis and dysregulation in human disease.

MeSH Terms
Amino Acid Sequence Animals Disease/etiology Female Hearing Loss/enzymology Humans Inflammation/enzymology JNK Mitogen-Activated Protein Kinases/chemistry,genetics,metabolism Liver/blood supply,injuries MAP Kinase Signaling System Models, Biological Molecular Sequence Data Neoplasms/enzymology Neural Tube Defects/enzymology Neurodegenerative Diseases/enzymology Pregnancy Reperfusion Injury/enzymology,etiology Sequence Homology, Amino Acid Signal Transduction
Chemicals
JNK Mitogen-Activated Protein Kinases
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Johnson Gary L
University of North Carolina at Chapel Hill, Department of Pharmacology, and Lineberger Comprehensive Cancer Center, 31-331 LCC Chapel Hill, NC 27599, USA. [email protected]
Nakamura Kazuhiro
References (100)
100 references, click to expand
  1. Inhibition of c-Jun N-terminal kinase decreases cardiomyocyte apoptosis and infarct size after myocardial ischemia and reperfusion in anaesthetized rats.
    Br J Pharmacol. 2004 Jul;142(6):953-60 PMID: 15210584
  2. An essential role of the JIP1 scaffold protein for JNK activation in adipose tissue.
    Genes Dev. 2004 Aug 15;18(16):1976-80 PMID: 15314024
  3. The MAPK/JNK signalling pathway offers potential therapeutic targets for the prevention of acquired deafness.
    Curr Drug Targets CNS Neurol Disord. 2004 Aug;3(4):325-32 PMID: 15379608
  4. Targeting JNK3 for the treatment of neurodegenerative disorders.
    Drug Discov Today. 2004 Nov 1;9(21):932-9 PMID: 15501728
  5. Phosphorylation of c-jun mediated by MAP kinases.
    Nature. 1991 Oct 17;353(6345):670-4 PMID: 1922387
  6. Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73.
    Nature. 1991 Dec 12;354(6353):494-6 PMID: 1749429
  7. Oncoprotein-mediated signalling cascade stimulates c-Jun activity by phosphorylation of serines 63 and 73.
    Mol Cell Biol. 1992 Aug;12(8):3507-13 PMID: 1630458
  8. A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf.
    Science. 1993 Apr 16;260(5106):315-9 PMID: 8385802
  9. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain.
    Cell. 1994 Mar 25;76(6):1025-37 PMID: 8137421
  10. The stress-activated protein kinase subfamily of c-Jun kinases.
    Nature. 1994 May 12;369(6476):156-60 PMID: 8177321
  11. JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation.
    Genes Dev. 1994 Dec 15;8(24):2996-3007 PMID: 8001819
  12. Cloning of rat MEK kinase 1 cDNA reveals an endogenous membrane-associated 195-kDa protein with a large regulatory domain.
    Proc Natl Acad Sci U S A. 1996 May 28;93(11):5291-5 PMID: 8643568
  13. Selective interaction of JNK protein kinase isoforms with transcription factors.
    EMBO J. 1996 Jun 3;15(11):2760-70 PMID: 8654373
  14. Stress-activated protein kinase/c-jun N-terminal kinase phosphorylates tau protein.
    J Neurochem. 1997 Apr;68(4):1736-44 PMID: 9084448
  15. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene.
    Nature. 1997 Oct 23;389(6653):865-70 PMID: 9349820
  16. A new rac target POSH is an SH3-containing scaffold protein involved in the JNK and NF-kappaB signalling pathways.
    EMBO J. 1998 Mar 2;17(5):1395-404 PMID: 9482736
  17. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene.
    Cancer Res. 1998 Jun 1;58(11):2339-42 PMID: 9622070
  18. Multiple docking sites on substrate proteins form a modular system that mediates recognition by ERK MAP kinase.
    Genes Dev. 1999 Jan 15;13(2):163-75 PMID: 9925641
  19. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human.
    Physiol Rev. 1999 Jan;79(1):143-80 PMID: 9922370
  20. Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation.
    Nat Genet. 1999 Mar;21(3):326-9 PMID: 10080190
  21. The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development.
    Neuron. 1999 Apr;22(4):667-76 PMID: 10230788
  22. The JIP group of mitogen-activated protein kinase scaffold proteins.
    Mol Cell Biol. 1999 Oct;19(10):7245-54 PMID: 10490659
  23. Identification of promoters bound by c-Jun/ATF2 during rapid large-scale gene activation following genotoxic stress.
    Mol Cell. 2004 Nov 19;16(4):521-35 PMID: 15546613
  24. Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis.
    Science. 2004 Nov 26;306(5701):1558-61 PMID: 15567863
  25. Increased tau phosphorylation on mitogen-activated protein kinase consensus sites and cognitive decline in transgenic models for Alzheimer's disease and FTDP-17: evidence for distinct molecular processes underlying tau abnormalities.
    Mol Cell Biol. 2005 Jan;25(1):278-93 PMID: 15601849
  26. MAP2K4/MKK4 expression in pancreatic cancer: genetic validation of immunohistochemistry and relationship to disease course.
    Clin Cancer Res. 2004 Dec 15;10(24):8516-20 PMID: 15623633
  27. Stress kinases involved in tau phosphorylation in Alzheimer's disease, tauopathies and APP transgenic mice.
    Neurotox Res. 2004;6(6):469-75 PMID: 15658002
  28. Beta-amyloid-induced neuronal apoptosis involves c-Jun N-terminal kinase-dependent downregulation of Bcl-w.
    J Neurosci. 2005 Feb 2;25(5):1149-58 PMID: 15689551
  29. Targeting the JNK signaling pathway for stroke and Parkinson's diseases therapy.
    Curr Drug Targets CNS Neurol Disord. 2005 Feb;4(1):63-7 PMID: 15723614
  30. Role of the JIP4 scaffold protein in the regulation of mitogen-activated protein kinase signaling pathways.
    Mol Cell Biol. 2005 Apr;25(7):2733-43 PMID: 15767678
  31. Targeting the JNK pathway as a therapeutic protective strategy for nervous system diseases.
    Rev Neurosci. 2005;16(1):57-67 PMID: 15810654
  32. c-Jun NH2-terminal kinase-interacting protein-3 facilitates phosphorylation and controls localization of amyloid-beta precursor protein.
    J Neurosci. 2005 Apr 13;25(15):3741-51 PMID: 15829626
  33. Conserved docking site is essential for activation of mammalian MAP kinase kinases by specific MAP kinase kinase kinases.
    Mol Cell. 2005 Apr 29;18(3):295-306 PMID: 15866172
  34. Therapeutic promise of JNK ATP-noncompetitive inhibitors.
    Trends Mol Med. 2005 May;11(5):232-9 PMID: 15882611
  35. JNK mediates hepatic ischemia reperfusion injury.
    J Hepatol. 2005 Jun;42(6):850-9 PMID: 15885356
  36. Mixed lineage kinase-c-jun N-terminal kinase signaling pathway: a new therapeutic target in Parkinson's disease.
    Mov Disord. 2005 Jun;20(6):653-64 PMID: 15719422
  37. Protective role for c-Jun in the cellular response to DNA damage.
    J Biol Chem. 2001 Jul 27;276(30):28546-53 PMID: 11352915
  38. Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand.
    J Neurosci. 2001 Oct 1;21(19):7551-60 PMID: 11567045
  39. Mutation rate of MAP2K4/MKK4 in breast carcinoma.
    Hum Mutat. 2002 Jan;19(1):81 PMID: 11754110
  40. Jun NH2-terminal kinase (JNK) interacting protein 1 (JIP1) binds the cytoplasmic domain of the Alzheimer's beta-amyloid precursor protein (APP).
    J Biol Chem. 2002 Feb 1;277(5):3767-75 PMID: 11724784
  41. Joint damage and inflammation in c-Jun N-terminal kinase 2 knockout mice with passive murine collagen-induced arthritis.
    Arthritis Rheum. 2002 Mar;46(3):818-23 PMID: 11920420
  42. Crystal structures of MAP kinase p38 complexed to the docking sites on its nuclear substrate MEF2A and activator MKK3b.
    Mol Cell. 2002 Jun;9(6):1241-9 PMID: 12086621
  43. Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease.
    J Neurochem. 2001 Jan;76(2):435-41 PMID: 11208906
  44. Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts.
    Nat Genet. 2002 Sep;32(1):201-5 PMID: 12161751
  45. Mixed-lineage kinase control of JNK and p38 MAPK pathways.
    Nat Rev Mol Cell Biol. 2002 Sep;3(9):663-72 PMID: 12209126
  46. Aberrant tau phosphorylation by glycogen synthase kinase-3beta and JNK3 induces oligomeric tau fibrils in COS-7 cells.
    J Biol Chem. 2002 Nov 1;277(44):42060-5 PMID: 12191990
  47. Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma.
    Cancer Res. 2002 Nov 15;62(22):6717-23 PMID: 12438272
  48. A central role for JNK in obesity and insulin resistance.
    Nature. 2002 Nov 21;420(6913):333-6 PMID: 12447443
  49. POSH acts as a scaffold for a multiprotein complex that mediates JNK activation in apoptosis.
    EMBO J. 2003 Jan 15;22(2):252-61 PMID: 12514131
  50. Ubiquitylation of MEKK1 inhibits its phosphorylation of MKK1 and MKK4 and activation of the ERK1/2 and JNK pathways.
    J Biol Chem. 2003 Jan 17;278(3):1403-6 PMID: 12456688
  51. C-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma.
    Clin Cancer Res. 2003 Jan;9(1):391-401 PMID: 12538493
  52. Activation of the JNK-AP-1 signal transduction pathway is associated with pathogenesis and progression of human osteosarcomas.
    Bone. 2003 Apr;32(4):364-71 PMID: 12689679
  53. JNK1 is required for maintenance of neuronal microtubules and controls phosphorylation of microtubule-associated proteins.
    Dev Cell. 2003 Apr;4(4):521-33 PMID: 12689591
  54. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia.
    Nat Med. 2003 Sep;9(9):1180-6 PMID: 12937412
  55. A peptide inhibitor of c-Jun N-terminal kinase protects against both aminoglycoside and acoustic trauma-induced auditory hair cell death and hearing loss.
    J Neurosci. 2003 Sep 17;23(24):8596-607 PMID: 13679429
  56. Regulation of MAP kinase signaling modules by scaffold proteins in mammals.
    Annu Rev Cell Dev Biol. 2003;19:91-118 PMID: 14570565
  57. RhoA binds to the amino terminus of MEKK1 and regulates its kinase activity.
    J Biol Chem. 2004 Jan 16;279(3):1872-7 PMID: 14581471
  58. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease.
    Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):665-70 PMID: 14704277
  59. Inhibition of c-Jun NH2-terminal kinase activity improves ischemia/reperfusion injury in rat lungs.
    J Immunol. 2004 Feb 15;172(4):2569-77 PMID: 14764730
  60. MAPK kinase kinases (MKKKs) as a target class for small-molecule inhibition to modulate signaling networks and gene expression.
    Curr Opin Chem Biol. 2005 Jun;9(3):325-31 PMID: 15939336
  61. Physiological regulation of the beta-amyloid precursor protein signaling domain by c-Jun N-terminal kinase JNK3 during neuronal differentiation.
    J Neurosci. 2005 Jun 8;25(23):5533-43 PMID: 15944381
  62. The limited role of NH2-terminal c-Jun phosphorylation in neuronal apoptosis: identification of the nuclear pore complex as a potential target of the JNK pathway.
    J Cell Biol. 2005 Aug 1;170(3):401-11 PMID: 16061693
  63. Context-specific inhibition of JNKs: overcoming the dilemma of protection and damage.
    Trends Pharmacol Sci. 2005 Sep;26(9):455-61 PMID: 16054242
  64. Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes.
    Diabetes. 2005 Dec;54 Suppl 2:S73-8 PMID: 16306344
  65. "Jnking" atherosclerosis.
    Cell Mol Life Sci. 2005 Nov;62(21):2487-94 PMID: 16231089
  66. Activation of MEKK1 by Rho GTPases.
    Methods Enzymol. 2006;406:468-78 PMID: 16472679
  67. The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma.
    Cancer Res. 2006 Feb 15;66(4):2264-70 PMID: 16489030
  68. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer.
    Cell. 2006 Feb 24;124(4):823-35 PMID: 16497591
  69. Cochlear implantation trauma and noise-induced hearing loss: Apoptosis and therapeutic strategies.
    Anat Rec A Discov Mol Cell Evol Biol. 2006 Apr;288(4):473-81 PMID: 16550592
  70. Jun signalling in the epidermis: From developmental defects to psoriasis and skin tumors.
    Int J Biochem Cell Biol. 2006;38(7):1043-9 PMID: 16423552
  71. Insulin resistance and improvements in signal transduction.
    Endocrine. 2006 Feb;29(1):73-80 PMID: 16622294
  72. Activated c-Jun is present in neurofibrillary tangles in Alzheimer's disease brains.
    Neurosci Lett. 2006 May 8;398(3):246-50 PMID: 16481106
  73. Interacting JNK-docking sites in MKK7 promote binding and activation of JNK mitogen-activated protein kinases.
    J Biol Chem. 2006 May 12;281(19):13169-79 PMID: 16533805
  74. GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling.
    Trends Endocrinol Metab. 2006 May-Jun;17(4):159-65 PMID: 16595179
  75. JNK regulation of oncogenesis.
    Mol Cells. 2006 Apr 30;21(2):167-73 PMID: 16682809
  76. MAPK signal specificity: the right place at the right time.
    Trends Biochem Sci. 2006 May;31(5):268-75 PMID: 16603362
  77. Tau therapeutic strategies for the treatment of Alzheimer's disease.
    Curr Top Med Chem. 2006;6(6):579-95 PMID: 16712493
  78. Direct interaction of the molecular scaffolds POSH and JIP is required for apoptotic activation of JNKs.
    J Biol Chem. 2006 Jun 2;281(22):15517-24 PMID: 16571722
  79. Signaling mechanisms underlying Abeta toxicity: potential therapeutic targets for Alzheimer's disease.
    CNS Neurol Disord Drug Targets. 2006 Jun;5(3):355-61 PMID: 16787235
  80. Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation.
    Proc Natl Acad Sci U S A. 2006 Jul 11;103(28):10544-51 PMID: 16807293
  81. Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17.
    Cancer Res. 1999 Nov 1;59(21):5483-7 PMID: 10554023
  82. Defective neural tube morphogenesis and altered apoptosis in the absence of both JNK1 and JNK2.
    Mech Dev. 1999 Dec;89(1-2):115-24 PMID: 10559486
  83. A conserved docking motif in MAP kinases common to substrates, activators and regulators.
    Nat Cell Biol. 2000 Feb;2(2):110-6 PMID: 10655591
  84. The gene MAPK8IP1, encoding islet-brain-1, is a candidate for type 2 diabetes.
    Nat Genet. 2000 Mar;24(3):291-5 PMID: 10700186
  85. Spatial, temporal and subcellular localization of islet-brain 1 (IB1), a homologue of JIP-1, in mouse brain.
    Eur J Neurosci. 2000 Feb;12(2):621-32 PMID: 10712642
  86. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307).
    J Biol Chem. 2000 Mar 24;275(12):9047-54 PMID: 10722755
  87. Activation of mitogen-activated protein kinases after transient forebrain ischemia in gerbil hippocampus.
    J Neurosci. 2000 Jun 15;20(12):4506-14 PMID: 10844020
  88. Docking domains and substrate-specificity determination for MAP kinases.
    Trends Biochem Sci. 2000 Sep;25(9):448-53 PMID: 10973059
  89. Alzheimer's disease: genes, proteins, and therapy.
    Physiol Rev. 2001 Apr;81(2):741-66 PMID: 11274343
  90. AP-1 in cell proliferation and survival.
    Oncogene. 2001 Apr 30;20(19):2390-400 PMID: 11402335
  91. A direct interaction between JNK1 and CrkII is critical for Rac1-induced JNK activation.
    EMBO J. 2001 Jul 2;20(13):3437-46 PMID: 11432831
  92. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis.
    J Clin Invest. 2001 Jul;108(1):73-81 PMID: 11435459
  93. TAK1 is a ubiquitin-dependent kinase of MKK and IKK.
    Nature. 2001 Jul 19;412(6844):346-51 PMID: 11460167
  94. Docking interactions in the c-Jun N-terminal kinase pathway.
    J Biol Chem. 2004 Mar 19;279(12):11843-52 PMID: 14699111
  95. Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential.
    Biochim Biophys Acta. 2004 Mar 11;1697(1-2):89-101 PMID: 15023353
  96. Use of cell-permeable peptides to prevent neuronal degeneration.
    Trends Mol Med. 2004 May;10(5):239-44 PMID: 15121051
  97. Functions of MAP kinases: insights from gene-targeting studies.
    J Biochem. 2004 Jun;135(6):653-6 PMID: 15213239
  98. Phosphorylation of microtubule-associated protein tau by isoforms of c-Jun N-terminal kinase (JNK).
    J Neurochem. 2004 Jul;90(2):352-8 PMID: 15228592
  99. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies.
    Curr Alzheimer Res. 2005 Jan;2(1):3-18 PMID: 15977985
  100. From JNK to pay dirt: jun kinases, their biochemistry, physiology and clinical importance.
    IUBMB Life. 2005 Apr-May;57(4-5):283-95 PMID: 16036612
Article Info
Journal
Biochimica et biophysica acta
Abbr.
Biochim Biophys Acta
ISSN
0006-3002
DOI
10.1016/j.bbamcr.2006.12.009
Email
[email protected]
Published
2007-08-00
Epub
2007-00-04
Pages
1341-8
Language
English
Region
Netherlands
NLM ID
0217513
PMCID
PMC1995559
Subset
IM
Grants
NIDDK NIH HHS · R01 DK037871 · United States
NIDDK NIH HHS · R01 DK037871-25A1 · United States
NIGMS NIH HHS · R37 GM030324 · United States
NIGMS NIH HHS · R37 GM030324-29 · United States
External Links
PubMed source DOI: 10.1016/j.bbamcr.2006.12.009 PMC Full Text
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2